Trending: Novartis Shares Climb on Guidance Lift
1240 GMT - Novartis is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. The Swiss pharma giant's shares surged after it lifted its full-year guidance on profit and sales that rose in the first quarter. The stock traded 5.4% higher at CHF92.03 earlier, making it one of today's best performers in the Stoxx 600 index. Shares of Novartis grew 7.2% year-to-date. In addition to Novartis's first-quarter results beating expectations, the company also confirmed it isn't experiencing any drug shortages following its strategic refocus on specialty medicines in its four core therapeutic areas, which it undertook last year, Chief Financial Officer Harry Kirsch said in a press call. Dow Jones & Co. owns Factiva. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 23, 2024 08:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing